Beijing Aosaikang Pharmaceutical Co., Ltd. clinical trials

Also known as ASK Pharm.

Part of Nanjing Aosaikang Investment Management Co., Ltd., which holds 34.20% as of 2025-12-31. Source

The registry lists 19 studies whose lead sponsor is Beijing Aosaikang Pharmaceutical Co., Ltd. or one of 2 companies grouped under it. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 27, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Get an email when these change. Save the Beijing Aosaikang Pharmaceutical Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Pipeline: 6 programmes

Each counted once: 6 with a study Beijing Aosaikang Pharmaceutical Co., Ltd. leads registered in the last two years.

Phase 1
Phase 2
Phase 3

All 3.

Sort

Programme	Main condition
ASKC202Phase 3 · 3 live · Carcinoma, Non-Small-Cell Lung · primary completion Dec 2026	Carcinoma, Non-Small-Cell Lung	Phase 3	3 / 3	Mar 2022	Oct 2027 est.
Phase 3 since 31 Jul 2025: Beijing Aosaikang Pharmaceutical Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next phase-3 primary completion: 31 Oct 2027, the registry's estimate, of NCT07109531study page ClinicalTrials.gov ↗ Next primary completion: Dec 2026, the registry's estimate, of NCT05306132 (phase 1) — when its main measure’s data collection ends, not when results are announced.study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.
ASK-120067Phase 3 · 2 live · Carcinoma, Non-Small-Cell Lung · primary completion Oct 2027	Carcinoma, Non-Small-Cell Lung	Phase 3	2 / 5	Apr 2018	Oct 2027 est.1 primary done, running
Phase 3 since 12 Oct 2019: Beijing Aosaikang Pharmaceutical Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next primary completion: 31 Oct 2027, the registry's estimate, of NCT07109531 (phase 3) — when its main measure’s data collection ends, not when results are announced.study page ClinicalTrials.gov ↗ 1 live study has an actual primary completion: the main measure is done and the study runs on (follow-up). Read from the registry as written: no join or match was needed.
ferric maltolST10Phase 3 · 0 live · Anemia, Iron-Deficiency	Anemia, Iron-Deficiency	Phase 3	0 / 1	Jul 2026	no phase-3 date ahead
Phase 3 since 22 Jul 2026: Beijing Aosaikang Pharmaceutical Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. One programme: ST10Judged by our rule (version a7fe2e4): the same study entry names both · 2026-11-14 Evidence: NCT05126901: “Ferric Maltol” (other names: Feraccru, Ferric Trimaltol, ST10, ST10-01)study page ClinicalTrials.gov ↗record history ↗ One programme: ST1001Judged by our rule (version a7fe2e4): the same study entry names both · 2026-11-14 Evidence: NCT05126901: “Ferric Maltol” (other names: Feraccru, Ferric Trimaltol, ST10, ST10-01)study page ClinicalTrials.gov ↗record history ↗ One programme: ST10021Judged by our rule (version a7fe2e4): the same study entry names both · 2026-11-14 Evidence: NCT01340872: “ST10-021” (other names: Ferric Trimaltol, Ferric maltol, Feraccru)study page ClinicalTrials.gov ↗record history ↗

3 from the earlier phases, besides the phase-3 view.

Sort

Programme	Main condition
5% ASKC200ASKC200Phase 2 · 2 live · Osteoarthritis	Osteoarthritis	Phase 2	2 / 2	Sep 2024	—1 estimated date passed1 primary done, running
Phase 2 since 26 Jul 2026: Beijing Aosaikang Pharmaceutical Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. 1 live study has an actual primary completion: the main measure is done and the study runs on (follow-up). 1 live study is past an estimated primary completion the registry has not updated. Read from the registry as written: no join or match was needed.
ASK0912Phase 2 · 1 live · Pneumonia, Bacterial · primary completion Oct 2027	Pneumonia, Bacterial	Phase 2	1 / 1	Aug 2026	Oct 2027 est.
Phase 2 since 2 Aug 2026: Beijing Aosaikang Pharmaceutical Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next primary completion: 20 Oct 2027, the registry's estimate, of NCT07759934 (phase 2) — when its main measure’s data collection ends, not when results are announced.study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.
ASKC189Phase 1 · 1 live · primary completion Nov 2028	—	Phase 1	1 / 1	Sep 2026	Nov 2028 est.
Phase 1 since 14 Sept 2026: Beijing Aosaikang Pharmaceutical Co., Ltd.’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov. Next primary completion: 30 Nov 2028, the registry's estimate, of NCT07836036 (phase 1) — when its main measure’s data collection ends, not when results are announced.study page ClinicalTrials.gov ↗ Read from the registry as written: no join or match was needed.

3 more — sign in to see them all, free: with every programme, filter by condition or phase and sort by first study or primary completion.

Save this set

Companies developing a programme in the same conditions as Beijing Aosaikang Pharmaceutical Co., Ltd.’s (4 conditions its studies of the last two years are mainly about), ranked by how directly they meet: a programme tested against the other’s drug, read from the study’s arms; then the conditions where both are in phase 3; then the conditions shared. Size plays no part.

AstraZeneca1 condition shared, 1 with both in phase 3: Carcinoma, Non-Small-Cell Lung
- Beijing Aosaikang Pharmaceutical Co., Ltd.’s ASKC202 in a combination vs osimertinib (US & EU rights: AstraZeneca) (Carcinoma, Non-Small-Cell Lung, NCT07897188)
- Beijing Aosaikang Pharmaceutical Co., Ltd.’s ASK-120067 in a combination vs Gefitinib (EU rights: AstraZeneca) (Carcinoma, Non-Small-Cell Lung, NCT04143607)
BioVersys SAS1 condition shared: Pneumonia, Bacterial
- Beijing Aosaikang Pharmaceutical Co., Ltd.’s ASK0912 in a combination vs Polymyxin B (most trials: BioVersys SAS) (Pneumonia, Bacterial, NCT07759934)
Jiangsu HengRui Medicine Co., Ltd.2 conditions shared, 1 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Pneumonia, Bacterial
Eli Lilly and Company2 conditions shared, 1 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Osteoarthritis
Sino Biopharmaceutical Limited2 conditions shared, 1 with both in phase 3: Carcinoma, Non-Small-Cell Lung, Pneumonia, Bacterial

Company	Conditions shared	Their phase 3 there	Where they meet, by arms
AstraZeneca7 programmes in shared conditions	1 · 1 with both in phase 3Carcinoma, Non-Small-Cell Lung	durvalumab, rilvegostomig, datopotamab deruxtecan	Beijing Aosaikang Pharmaceutical Co., Ltd.’s ASKC202 in a combination vs osimertinib (US & EU rights: AstraZeneca) (Carcinoma, Non-Small-Cell Lung, NCT07897188) Beijing Aosaikang Pharmaceutical Co., Ltd.’s ASK-120067 in a combination vs Gefitinib (EU rights: AstraZeneca) (Carcinoma, Non-Small-Cell Lung, NCT04143607)
BioVersys SAS2 programmes in shared conditions	1Pneumonia, Bacterial	BV100, Polymyxin B	Beijing Aosaikang Pharmaceutical Co., Ltd.’s ASK0912 in a combination vs Polymyxin B (most trials: BioVersys SAS) (Pneumonia, Bacterial, NCT07759934)
Jiangsu HengRui Medicine Co., Ltd.12 programmes in shared conditions	2 · 1 with both in phase 3Carcinoma, Non-Small-Cell Lung, Pneumonia, Bacterial	ruzaltatug rezetecan, adebrelimab, aumolertinib +3	no study of one against the other’s drug
Eli Lilly and Company5 programmes in shared conditions	2 · 1 with both in phase 3Carcinoma, Non-Small-Cell Lung, Osteoarthritis	selpercatinib, olomorasib, eloralintide +1	no study of one against the other’s drug
Sino Biopharmaceutical Limited3 programmes in shared conditions	2 · 1 with both in phase 3Carcinoma, Non-Small-Cell Lung, Pneumonia, Bacterial	FHND-9041	no study of one against the other’s drug

133 more companies — sign in to see them all, free.

“Registry” is the highest phase of Beijing Aosaikang Pharmaceutical Co., Ltd.’s own registered studies; Beijing Aosaikang Pharmaceutical Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Beijing Aosaikang Pharmaceutical Co., Ltd.’s studies test, most open studies first — 9 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

ASKC2022 in phase 3
3 open · 3
ASK-1200672 in phase 3
1 open · 5
aflutinib1 in phase 3
0 open · 4
omectatug1 in phase 3
0 open · 3
ferric maltol1 in phase 3
0 open · 1
Itraconazole
0 open · 1
Rifampin
0 open · 1
sintilimab
0 open · 1
tislelizumab
0 open · 1

Coming up

5 of Beijing Aosaikang Pharmaceutical Co., Ltd.’s studies under way reach primary completion within a year, 2 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

NNov ’26’26
3DDec
JJan ’27’27
FFeb
MMar
AApr
MMay
JJun
JJul
AAug
SSep
2OOct
NNov

All 5

Dec 2026ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinomaomectatug · Phase 3 · NCT06206733
Dec 2026Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067ASKC202 · NCT05306132
Dec 2026A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.NCT05867420
Oct 2027ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyASKC202, ASK-120067 · Phase 3 · NCT07109531
Oct 2027ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaNCT07759934

Add all 5 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCOct 27, 2026NCT07897188

All 19 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

Open now737%Recruiting 4 · Not yet recruiting 3
Under way, not recruiting526%
Completed316%
Status unknown or other421%

Phase

Phase 112
Phase 26
Phase 35

Where

China17
United States1
Australia1

Over the years

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Beijing Aosaikang Pharmaceutical Co., Ltd..

Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Subsidiary
Something wrong?
What is wrong with this name?Not part of Beijing Aosaikang Pharmaceutical Co., Ltd.Wrong relationship to Beijing Aosaikang Pharmaceutical Co., Ltd.Something else
What is right?A source, if you have one
No account needed. Please leave out personal details.
14 studies →
AskGene Pharma, Inc.
Subsidiary
Something wrong?
What is wrong with this name?Not part of Beijing Aosaikang Pharmaceutical Co., Ltd.Wrong relationship to Beijing Aosaikang Pharmaceutical Co., Ltd.Something else
What is right?A source, if you have one
No account needed. Please leave out personal details.
5 studies →

Studies

Recruiting first, then most recently updated. Showing 19 of 19.

ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07897188Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS MutationsNot yet recruitingNCT07836036Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyRecruitingNCT07109531Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial PneumoniaRecruitingNCT07759934Phase 2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.RecruitingNCT05867420Phase 1/2
Sponsor listed in the registry: AskGene Pharma, Inc.
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingNCT05306132Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee PainNot yet recruitingNCT06614608Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaActive, not recruitingNCT06206733Phase 3
Sponsor listed in the registry: AskGene Pharma, Inc.
ASKC200 for Knee Osteoarthritis PainActive, not recruitingNCT07742852Phase 2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Safety and Efficacy Study of Ferric Maltol To Treat Iron Deficiency Anaemia in Chinese Patients With Inflammatory Bowel DiseaseCompletedNCT07739368Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT04632108Phase 1/2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingNCT05632939Phase 1/2
Sponsor listed in the registry: AskGene Pharma, Inc.
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingNCT04143607Phase 3
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
A Phase 1 Study of ASKG315 in Patients With Advanced Solid TumorsStatus unknownNCT05509985Phase 1
Sponsor listed in the registry: AskGene Pharma, Inc.
A Study of ASKG315 in Patients With Advanced Solid Tumors.Status unknownNCT05554666Phase 1
Sponsor listed in the registry: AskGene Pharma, Inc.
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or ItraconazoleCompletedNCT05631678Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerStatus unknownNCT03502850Phase 1/2
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy SubjectsCompletedNCT04360915Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy SubjectsStatus unknownNCT03115762Phase 1
Sponsor listed in the registry: Jiangsu Aosaikang Pharmaceutical Co., Ltd.